🚀 Join Us at World CB & CDx 2024! 🚀 The CellCarta team is heading to Boston, USA, for the 14th World Clinical Biomarkers & Companion Diagnostics Summit. 🌐 Meet us at the event to: • Engage with our experts and explore our comprehensive CRO services • Discuss opportunities to advance the next generation of precision medicine 📅 Event Details: 🗓 September 4-6, 2024 📍Boston, MA Book a meeting with us here: https://bit.ly/3HQzLHL #CDx #Biomarkers #PrecisionMedicine #SpatialBiology #CellCarta #WorldCDX
About us
As a global leader in precision medicine testing services, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials. CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as digital pathology/AI and sample management, logistics and kitting services. At CellCarta we are experts at assessing the immune system, whether in the context of oncology, infectious diseases, or autoimmune diseases. With a proven track record in other therapeutic areas as, such as neurological and metabolic disorders, we handle all human biological specimens and deploy relevant technologies to extract valuable information for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational research, clinical trials, and diagnostic applications. Reflecting our commitment to quality, our sites hold the appropriate accreditations to support your regulatory requirements, including CAP, CLIA, ISO15189, ISO27001 and ISO13485.
- Website
-
https://cellcarta.com/
External link for CellCarta
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Montreal, Quebec
- Type
- Privately Held
- Specialties
- CRO Laboratory, Oncology, Auto-Immune Diseases, Infectious Diseases, Neurological and Metabolic Disorders, Biomarker, Immune Monitoring, Immunology, Histopathology, Immunohistochemistry, Genomics, Proteomics, Bioinformatics, Mass Spectrometry, Flow Cytometry, ELISpot, Neo-Epitope Discovery, Biologics, Mass Cytometry, Sample Logistics, Kitting, Sample Procurement Tissue Analysis, Molecular Techniques, Tumor Profiling, Personalized Medicine, Biotechnology,, Immunofluorescence, Fluorescence in situ hybridization, Genomics, Pathology, and Pharmaceuticals
Locations
Employees at CellCarta
Updates
-
CellCarta reposted this
Earlier this year, I had the opportunity to chat with Dr. Scott Gottlieb, the former FDA Commissioner, at a Healthcare Summit in New York. Dr. Gottlieb is a unique blend of scientist, regulator, and investor, all rolled into one. Our brief conversation touched on so many fascinating topics that I’m thrilled to bring a deeper discussion to you in this upcoming fireside chat. I’ll be exploring key areas with Dr. Gottlieb, including CDx development and the transformative role of ML/AI in pathology biomarkers. For those passionate about cell therapy, it’s a great opportunity to hear from him, under whose watch the FDA approved the first CAR-T therapy! We’ll also delve into the intriguing intersection of metabolism (GLP-1 agonists, anyone?), immunology, and oncology. Dr Gottlieb’s going to bring some great stuff. Please join us! Register now: https://bit.ly/3X8fFkQ #celltherapy #PrecisionMedicine #Immunooncology #DigitalPathology #CellCarta
-
-
Our much-anticipated webcast series Let’s Talk is welcoming Scott Gottlieb, former FDA commissioner. Register now: https://bit.ly/3X8fFkQ The latest on regulatory & biomarker development will be discussed. Submit a question before the event and save your spot for Sept. 12th - 11am EST. Don't let this opportunity slip away! #BiomarkerInsights #DrugDevelopment #CellTherapy
-
-
Spatial biology provides a deeper understanding of complex biological paradigms, improving the efficiency of therapy development. 👉 https://bit.ly/4dDGpPm Wondering how it could help you? Look no further! 🤩 Integrating spatial biology into therapy development workflows offers several benefits: ✨Aids understandings of tissue microenvironments ✨Addresses disease heterogeneity ✨Enables biomarker identification ✨Enhances drug distribution and efficacy studies ✨Elucidates mechanism of action ✨Improves immune response profiling ✨Builds understanding of drug resistance …and much more. Read on to dig deeper! #SpatialBiology #DrugResponse #PersonalizedMedicine #PrecisionMedicine
-
-
PBMC processing following robust, standardized SOPs to ensure quality data. Sounds interesting? https://bit.ly/4foNlll Our state-of-the-art facility in Naperville, U.S. offers PBMC processing and delivers: ⭐ Fast turn arounds to support short stability windows, with samples collected, shipped and processed within 24hrs ⭐ Capabilities with both Ficoll and CPT tubes that lead to >90% cell viability ⭐ Onsite biorepository services Discover why we’re the CRO partner of choice for PBMC processing, but also sample logistics the world over. 🌏 https://bit.ly/4cSIvuL #CellCarta #PrecisionMedicine #CellTherapy
-
Single-cell sequencing can uncover insights that flow cytometry and bulk RNA-seq may miss. Find out more about the potential of this method: https://bit.ly/3XcMTiQ
This content isn’t available here
Access this content and more in the LinkedIn app
-
Join us for an exclusive webcast with Scott Gottlieb, former FDA commissioner, and Christopher Ung, Chief Scientific Business Officer at CellCarta. Register here: https://bit.ly/4dtEXQ1 Scott and Christopher will provide valuable insights on the latest regulations and advancements in biomarker development, including: ⭐ A retrospective and forward-looking view on cell therapies ⭐ Navigating the FDA final rule vs. the VALID Act ⭐ The impact of the 2023 CDx pilot program ⭐ T cell health in immune oncology & metabolic drug development ⭐ Transforming drug development with AI-driven digital pathology Don’t miss this opportunity to learn directly from industry experts on September 12th at 11am EST. Secure your spot today!
This content isn’t available here
Access this content and more in the LinkedIn app
-
👋Meet Dr. Paula López Arias, a surgical pathologist from Colombia who now works in CellCarta’s pathology department. Discover how she and the rest of the team can support your research: https://bit.ly/3VEmMiR Dr. López Arias has interests in oncopathology, molecular pathology, and digital pathology and strong expertise in gastrointestinal biopsies. Meet the rest of our pathology team and learn how they help drive innovation in biomarker testing. #Pathology #Biomarkers
-
-
As a global leader in flow cytometry, our experts are ready with custom solutions and support to maximize insights for clinical studies of all sizes. Learn More: https://bit.ly/3wDzK83
-
📣Join us for an exclusive webcast featuring Scott Gottlieb, former FDA commissioner, and Christopher Ung, CellCarta’s Chief Scientific Business Officer. https://bit.ly/3X8fFkQ Scott and Christopher will discuss the latest in regulatory and biomarker development, including: ⭐Cell therapies: a look back and forward ⭐Navigating the FDA final rule vs valid act ⭐Impact of the 2023 CDx pilot program ⭐T cell health in immune oncology & metabolic drug development ⭐Revolutionizing drug development with AI digital pathology Don’t miss your chance to hear directly from an industry leader on September 12th at 11am EST. Reserve your spot now!
-